Concepts (180)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Head and Neck Neoplasms | 14 | 2024 | 2734 | 1.880 |
Why?
|
Radiosurgery | 6 | 2023 | 1329 | 1.600 |
Why?
|
Oropharyngeal Neoplasms | 5 | 2023 | 477 | 1.300 |
Why?
|
Medical Oncology | 5 | 2021 | 2265 | 0.980 |
Why?
|
Temporal Muscle | 1 | 2023 | 37 | 0.930 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 6 | 2022 | 5221 | 0.920 |
Why?
|
Growth Charts | 1 | 2023 | 61 | 0.900 |
Why?
|
Artificial Intelligence | 8 | 2024 | 2214 | 0.890 |
Why?
|
Medulloblastoma | 2 | 2017 | 683 | 0.780 |
Why?
|
Lung Neoplasms | 8 | 2023 | 13102 | 0.690 |
Why?
|
Bibliometrics | 1 | 2022 | 339 | 0.650 |
Why?
|
Sarcopenia | 1 | 2023 | 368 | 0.640 |
Why?
|
Radiotherapy, Intensity-Modulated | 3 | 2021 | 806 | 0.630 |
Why?
|
Lymphatic Metastasis | 4 | 2019 | 2924 | 0.600 |
Why?
|
Cobalt Radioisotopes | 1 | 2016 | 76 | 0.590 |
Why?
|
Sezary Syndrome | 1 | 2017 | 76 | 0.570 |
Why?
|
Papillomavirus Infections | 3 | 2023 | 1587 | 0.550 |
Why?
|
Mycosis Fungoides | 1 | 2017 | 163 | 0.530 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2018 | 3479 | 0.520 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 806 | 0.520 |
Why?
|
Brachytherapy | 2 | 2020 | 1248 | 0.510 |
Why?
|
Cancer Care Facilities | 1 | 2017 | 402 | 0.490 |
Why?
|
Neoplasm Staging | 12 | 2024 | 11031 | 0.490 |
Why?
|
Radiotherapy, Adjuvant | 3 | 2017 | 1770 | 0.440 |
Why?
|
Combined Modality Therapy | 6 | 2020 | 8642 | 0.440 |
Why?
|
Cerebellar Neoplasms | 1 | 2017 | 587 | 0.400 |
Why?
|
Prostatectomy | 1 | 2020 | 1890 | 0.400 |
Why?
|
Glioma | 2 | 2024 | 3401 | 0.400 |
Why?
|
Brain Neoplasms | 3 | 2024 | 8863 | 0.390 |
Why?
|
Carcinoma | 1 | 2023 | 2375 | 0.390 |
Why?
|
Carcinoma, Squamous Cell | 5 | 2024 | 4034 | 0.370 |
Why?
|
Neoplasms | 7 | 2023 | 21683 | 0.350 |
Why?
|
Radiotherapy | 1 | 2016 | 1533 | 0.350 |
Why?
|
Radiotherapy Dosage | 7 | 2021 | 2879 | 0.300 |
Why?
|
Retrospective Studies | 20 | 2024 | 77449 | 0.290 |
Why?
|
Algorithms | 5 | 2024 | 13881 | 0.280 |
Why?
|
Tomography, X-Ray Computed | 8 | 2024 | 20129 | 0.280 |
Why?
|
Inpatients | 1 | 2017 | 2518 | 0.260 |
Why?
|
Humans | 53 | 2024 | 744343 | 0.250 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2023 | 288 | 0.250 |
Why?
|
Prognosis | 12 | 2023 | 29063 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9239 | 0.230 |
Why?
|
Adenocarcinoma | 1 | 2021 | 6364 | 0.230 |
Why?
|
Aged, 80 and over | 17 | 2019 | 57776 | 0.220 |
Why?
|
Fund Raising | 1 | 2023 | 47 | 0.220 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.220 |
Why?
|
Survival Analysis | 9 | 2019 | 10252 | 0.210 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2023 | 1624 | 0.210 |
Why?
|
Medical Tourism | 1 | 2023 | 57 | 0.210 |
Why?
|
Lymph Nodes | 4 | 2023 | 3474 | 0.200 |
Why?
|
Thoracic Neoplasms | 1 | 2023 | 268 | 0.200 |
Why?
|
ROC Curve | 2 | 2019 | 3527 | 0.200 |
Why?
|
Nomograms | 1 | 2022 | 228 | 0.190 |
Why?
|
Male | 26 | 2024 | 350118 | 0.190 |
Why?
|
Prostatic Neoplasms | 2 | 2020 | 11124 | 0.180 |
Why?
|
Survival Rate | 3 | 2020 | 12788 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 11524 | 0.180 |
Why?
|
Radiation Dosage | 2 | 2019 | 1928 | 0.170 |
Why?
|
Aged | 22 | 2024 | 163280 | 0.170 |
Why?
|
Female | 27 | 2024 | 380194 | 0.170 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6538 | 0.160 |
Why?
|
Selection Bias | 1 | 2020 | 371 | 0.160 |
Why?
|
Mouth Neoplasms | 1 | 2024 | 601 | 0.160 |
Why?
|
Oligodendroglioma | 1 | 2019 | 279 | 0.150 |
Why?
|
Propensity Score | 3 | 2019 | 1781 | 0.150 |
Why?
|
Alphapapillomavirus | 1 | 2020 | 221 | 0.150 |
Why?
|
Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 207 | 0.140 |
Why?
|
Radiation Injuries | 1 | 2023 | 1180 | 0.140 |
Why?
|
Radiotherapy, Conformal | 1 | 2019 | 548 | 0.140 |
Why?
|
Funnel Chest | 1 | 2016 | 71 | 0.130 |
Why?
|
Middle Aged | 18 | 2024 | 213383 | 0.130 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39050 | 0.130 |
Why?
|
SEER Program | 1 | 2020 | 1508 | 0.130 |
Why?
|
Comparative Effectiveness Research | 1 | 2020 | 681 | 0.130 |
Why?
|
Relative Biological Effectiveness | 1 | 2016 | 323 | 0.130 |
Why?
|
Medical Informatics | 1 | 2021 | 745 | 0.120 |
Why?
|
Astrocytoma | 1 | 2019 | 790 | 0.120 |
Why?
|
Radiation Oncology | 1 | 2020 | 555 | 0.120 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2024 | 2043 | 0.120 |
Why?
|
Pleural Neoplasms | 1 | 2019 | 607 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 1076 | 0.110 |
Why?
|
Biopsy | 2 | 2024 | 6756 | 0.110 |
Why?
|
Mesothelioma | 1 | 2019 | 818 | 0.110 |
Why?
|
Patient Selection | 2 | 2022 | 4215 | 0.110 |
Why?
|
Treatment Outcome | 6 | 2019 | 63114 | 0.110 |
Why?
|
Disease-Free Survival | 2 | 2021 | 6895 | 0.090 |
Why?
|
Child | 4 | 2024 | 77709 | 0.090 |
Why?
|
Adult | 15 | 2024 | 214055 | 0.090 |
Why?
|
Postoperative Care | 1 | 2016 | 1486 | 0.090 |
Why?
|
Logistic Models | 2 | 2022 | 13408 | 0.090 |
Why?
|
Cohort Studies | 4 | 2024 | 40561 | 0.090 |
Why?
|
United States | 6 | 2023 | 69872 | 0.080 |
Why?
|
Central Nervous System Neoplasms | 1 | 2017 | 895 | 0.080 |
Why?
|
Nanomedicine | 1 | 2011 | 304 | 0.080 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2012 | 721 | 0.070 |
Why?
|
Research Design | 1 | 2022 | 5987 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2023 | 19905 | 0.070 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7785 | 0.070 |
Why?
|
Neoplasms, Experimental | 1 | 2011 | 1276 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.070 |
Why?
|
Young Adult | 5 | 2019 | 56430 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2024 | 8949 | 0.070 |
Why?
|
Molecular Imaging | 1 | 2012 | 828 | 0.060 |
Why?
|
Neovascularization, Pathologic | 2 | 2012 | 2635 | 0.060 |
Why?
|
Decision Making | 1 | 2019 | 3887 | 0.060 |
Why?
|
Delivery of Health Care | 1 | 2022 | 5319 | 0.060 |
Why?
|
Palliative Care | 1 | 2019 | 3493 | 0.060 |
Why?
|
Respiratory Mechanics | 1 | 2008 | 686 | 0.060 |
Why?
|
Heart | 1 | 2016 | 4467 | 0.060 |
Why?
|
Papillomaviridae | 2 | 2020 | 1119 | 0.050 |
Why?
|
Adolescent | 5 | 2017 | 85781 | 0.050 |
Why?
|
Flail Chest | 1 | 2000 | 15 | 0.050 |
Why?
|
Nanoparticles | 1 | 2012 | 1905 | 0.050 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2008 | 1184 | 0.050 |
Why?
|
Movement | 1 | 2008 | 1471 | 0.050 |
Why?
|
Thorax | 1 | 2024 | 547 | 0.050 |
Why?
|
Breast Neoplasms | 2 | 2019 | 20822 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2012 | 2529 | 0.050 |
Why?
|
Risk Factors | 4 | 2019 | 72290 | 0.040 |
Why?
|
Artifacts | 1 | 2008 | 1904 | 0.040 |
Why?
|
Databases, Factual | 3 | 2019 | 7729 | 0.040 |
Why?
|
Thoracic Injuries | 1 | 2000 | 272 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2019 | 4851 | 0.040 |
Why?
|
Demography | 1 | 2023 | 1656 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2014 | 15076 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2019 | 876 | 0.040 |
Why?
|
Risk Assessment | 1 | 2019 | 23338 | 0.040 |
Why?
|
Child, Preschool | 2 | 2017 | 41006 | 0.040 |
Why?
|
Oligopeptides | 2 | 2012 | 1189 | 0.030 |
Why?
|
Quality of Life | 1 | 2017 | 12804 | 0.030 |
Why?
|
Obesity | 1 | 2018 | 12745 | 0.030 |
Why?
|
Thoracic Wall | 1 | 2016 | 203 | 0.030 |
Why?
|
Imaging, Three-Dimensional | 1 | 2008 | 4042 | 0.030 |
Why?
|
Cranial Irradiation | 1 | 2017 | 401 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2023 | 35421 | 0.030 |
Why?
|
Tumor Burden | 1 | 2019 | 1915 | 0.030 |
Why?
|
Neck Dissection | 1 | 2014 | 197 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2019 | 1275 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6773 | 0.030 |
Why?
|
Integrin alphaVbeta3 | 1 | 2012 | 111 | 0.030 |
Why?
|
Emulsions | 1 | 2011 | 156 | 0.020 |
Why?
|
Mastectomy | 1 | 2019 | 1793 | 0.020 |
Why?
|
Choice Behavior | 1 | 2017 | 803 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2017 | 3508 | 0.020 |
Why?
|
Breast | 1 | 2019 | 1969 | 0.020 |
Why?
|
Prednisolone | 1 | 2011 | 334 | 0.020 |
Why?
|
Age of Onset | 1 | 2017 | 3271 | 0.020 |
Why?
|
Fluorescence | 1 | 2012 | 751 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2012 | 1799 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2011 | 712 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2459 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 2017 | 1377 | 0.020 |
Why?
|
Recurrence | 1 | 2019 | 8340 | 0.020 |
Why?
|
Photons | 1 | 2011 | 588 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2011 | 2085 | 0.020 |
Why?
|
Drug Carriers | 1 | 2011 | 693 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2017 | 2728 | 0.020 |
Why?
|
Regression Analysis | 1 | 2015 | 6459 | 0.020 |
Why?
|
Surgical Flaps | 1 | 2014 | 1640 | 0.020 |
Why?
|
Odds Ratio | 1 | 2017 | 9849 | 0.020 |
Why?
|
Time Factors | 2 | 2017 | 40075 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12245 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 2008 | 885 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12354 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2011 | 2107 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.010 |
Why?
|
Registries | 1 | 2017 | 8089 | 0.010 |
Why?
|
Body Mass Index | 1 | 2018 | 12720 | 0.010 |
Why?
|
New Jersey | 1 | 2000 | 290 | 0.010 |
Why?
|
Lipids | 1 | 2011 | 3305 | 0.010 |
Why?
|
Colonic Neoplasms | 1 | 2011 | 2541 | 0.010 |
Why?
|
Contrast Media | 1 | 2012 | 5300 | 0.010 |
Why?
|
Injury Severity Score | 1 | 2000 | 1014 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2017 | 25625 | 0.010 |
Why?
|
Trauma Centers | 1 | 2000 | 890 | 0.010 |
Why?
|
Infant | 1 | 2017 | 35136 | 0.010 |
Why?
|
Mice | 2 | 2012 | 81183 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18029 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14722 | 0.010 |
Why?
|
Animals | 2 | 2012 | 168757 | 0.010 |
Why?
|
Concepts
(180)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(75)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_